T A Rupprecht1, C Lechner, H Tumani, V Fingerle. 1. Abteilung für Neurologie, AmperKliniken Dachau, Krankenhausstr. 15, 82131, Dachau, Deutschland, Tobias.Rupprecht@amperkliniken.de.
Abstract
BACKGROUND: The level of CXCL13 is a cerebrospinal fluid (CSF) biomarker for acute Lyme neuroborreliosis (LNB) with a high sensitivity. As the concentration rapidly declines during antibiotic therapy CXCL13 can also be used as a follow-up parameter. However, CXCL13 is not yet in use as a routine parameter due to concerns about the specificity. OBJECTIVES: The sensitivity, specificity and predictive value of CXCL13 in the clinical routine work-up of suspected LNB was analyzed. MATERIAL AND METHODS: Since July 2010 the CSF of all patients (n = 204) with suspected acute LNB was not only analyzed for the routine parameters (i.e. pleocytosis and intrathecal production of Borrelia-specific antibodies, AI) but also for CXCL13. In cases of incongruent findings, a follow-up puncture after antibiotic therapy was carried out. The cut-off level for acute LNB was set at 250 pg/ml. RESULTS: This study included 179 patients who were not pretreated with antibiotics. Of these patients 15 suffered from definite LNB, 3 had a probable LNB and all had a CXCL13 value above the cut-off level. Only 2 of the 161 patients with a non-LNB diagnosis (both with a lymphoma) had a CXCL13 value in the CSF higher than 250 pg/ml. Especially noteworthy were two patients without pleocytosis in the CSF but with CXCL13 levels above the cut-off level in whom LNB could be confirmed in the follow-up CSF analysis. CONCLUSIONS: The biomarker CXCL13 has a higher sensitivity (100 % vs. 87 %) with a specificity (99 %) comparable with the established diagnostic markers for LNB, e.g. CSF pleocytosis and Borrelia-AI in the investigated patient population. The negative predictive value of CXCL13 is 100 %. Therefore, a normal CXCL13 level virtually excludes LNB. In the clinical routine CXCL13 is a valuable and practical diagnostic marker for LNB and can even detect an acute LNB in patients without CSF pleocytosis.
BACKGROUND: The level of CXCL13 is a cerebrospinal fluid (CSF) biomarker for acute Lyme neuroborreliosis (LNB) with a high sensitivity. As the concentration rapidly declines during antibiotic therapy CXCL13 can also be used as a follow-up parameter. However, CXCL13 is not yet in use as a routine parameter due to concerns about the specificity. OBJECTIVES: The sensitivity, specificity and predictive value of CXCL13 in the clinical routine work-up of suspected LNB was analyzed. MATERIAL AND METHODS: Since July 2010 the CSF of all patients (n = 204) with suspected acute LNB was not only analyzed for the routine parameters (i.e. pleocytosis and intrathecal production of Borrelia-specific antibodies, AI) but also for CXCL13. In cases of incongruent findings, a follow-up puncture after antibiotic therapy was carried out. The cut-off level for acute LNB was set at 250 pg/ml. RESULTS: This study included 179 patients who were not pretreated with antibiotics. Of these patients 15 suffered from definite LNB, 3 had a probable LNB and all had a CXCL13 value above the cut-off level. Only 2 of the 161 patients with a non-LNB diagnosis (both with a lymphoma) had a CXCL13 value in the CSF higher than 250 pg/ml. Especially noteworthy were two patients without pleocytosis in the CSF but with CXCL13 levels above the cut-off level in whom LNB could be confirmed in the follow-up CSF analysis. CONCLUSIONS: The biomarker CXCL13 has a higher sensitivity (100 % vs. 87 %) with a specificity (99 %) comparable with the established diagnostic markers for LNB, e.g. CSF pleocytosis and Borrelia-AI in the investigated patient population. The negative predictive value of CXCL13 is 100 %. Therefore, a normal CXCL13 level virtually excludes LNB. In the clinical routine CXCL13 is a valuable and practical diagnostic marker for LNB and can even detect an acute LNB in patients without CSF pleocytosis.
Authors: N Wutte; A Berghold; S Löffler; W Zenz; E Daghofer; I Krainberger; G Kleinert; E Aberer Journal: Acta Neurol Scand Date: 2011-02-15 Impact factor: 3.209
Authors: Lars Fischer; Agnieszka Korfel; Sebastian Pfeiffer; Philipp Kiewe; Hans-Dieter Volk; Hüsniye Cakiroglu; Thomas Widmann; Eckhard Thiel Journal: Clin Cancer Res Date: 2009-09-22 Impact factor: 12.531
Authors: Markus C Kowarik; Sabine Cepok; Johann Sellner; Verena Grummel; Martin S Weber; Thomas Korn; Achim Berthele; Bernhard Hemmer Journal: J Neuroinflammation Date: 2012-05-16 Impact factor: 8.322
Authors: Daniel Bremell; Niklas Mattsson; Mikael Edsbagge; Kaj Blennow; Ulf Andreasson; Carsten Wikkelsö; Henrik Zetterberg; Lars Hagberg Journal: BMC Neurol Date: 2013-01-07 Impact factor: 2.474
Authors: Khutso M Mothapo; Marcel M Verbeek; Lieven B van der Velden; C Wim Ang; Peter P Koopmans; Andre van der Ven; Foekje Stelma Journal: J Clin Microbiol Date: 2015-03-18 Impact factor: 5.948
Authors: M M Remy; N Schöbi; L Kottanattu; S Pfister; A Duppenthaler; F Suter-Riniker Journal: J Neuroinflammation Date: 2017-08-31 Impact factor: 8.322